Samsung quietly layout the medical industry, early industry are Samsung, medical, and health-IT information
Map of the health of the world's leading consumer electronics group are increasingly sophisticated.
On May 8, 2016, Samsung Seoul hospital with Sun harmony hospital reached an agreement, the two sides will in health management, multidisciplinary consultations, intensive treatment and personnel training cooperation.
Samsung Seoul hospital funded by the Samsung Group in 1994, is now ranked Korea one of the top five hospitals each year from more than 150 countries, more than 30,000 patients, its high-end medical examinations and treatment in the world; Sun harmony hospital is China's first large investments by insurers in general hospitals, by JCI and "top three" standard construction, was typical of the social capital of medical cases. Move seen as Samsung Group to enter the important step of China's high-end medical services.
Not only hospitals, 23 trillion won from 2010-year energy and environment and health investment plan, Samsung Group "medical + pharmaceutical + medical" three-pillar model into the prospects for broader health industry, after five years of low profile, and has been initially formed with prospects for future development of medical and health domain.
Specific,, in medical service, Samsung Seoul hospital a sweep "Korea beauty" of inherent impression, to cure rate and price advantage, main "admitted type" high-end medical and heavy syndrome treatment; in pharmaceutical field, select most with prospects of biological pharmaceutical and the delegate production (CMO) this a scarce supply link, became world third big (CMO) suppliers; in digital medical, low-key integration medical, and technology resources, build has from health management to treatment core of integrated medical platform.
Industry analysts, three major sections are aimed at the most advanced market segment in the healthcare industry, appears to be dispersed, actually constitute the support and echo each other's medical and health industry. More valuable is, Samsung for the original construction of the electronics industry, operating experience, skillfully ported to health, therefore, investing in efficiency, productivity and manufacturing cost, has the potential to create world's highest competitive within a short time, resulting in a unique "Samsung transformation logic."
It can be predicted that in the 21st century, health care industry will be one of Samsung's core business.
Medical services section: cure rates are not lost in Europe and America, cost advantages
Cooperation with Sun harmony hospital is not the Samsung Group to China for the first time precise medical services initiative.
On March 4, Samsung hospital in Seoul and Beijing reached a similar agreement the Matilda and War Memorial Hospital, which is a subsidiary of BoE private high-end General Hospital. Samsung hopes to severe treatment and high-end medical examinations was introduced into China.
In fact, when it comes to Korea medical, cosmetic plastic surgery was a big mistake, data show that health care spending is equivalent to United States under 1/4, Korea is in total life expectancy, died of heart disease on indicators such as access to the United States more effective. Europe, the Middle East, China and other countries and regions often employ Korea doctors to treat.
Specific to Samsung hospital in Seoul, 10% Korea cancer patients, 1/4, video-assisted Thoracoscopic surgery in the Hospital of lung cancer patients complete, gastric cancer, colorectal cancer and hepatocellular carcinoma postoperative mortality and recurrence rate in Korea is also lower. Seoul hospitals adhering to the principle of effective and side effects minimized.
"Cancer tool" for proton therapy, for example, in 2015, the Samsung Seoul hospital introduced the advanced radiotherapy methods, through one hundred tons of equipment, hit speeds of about 2/3 times the speed of light particles in order to destroy cancer cells, and normal human tissues and very few injuries.
"Particle therapy collaboration organization" statistics, by the end of 2014, the global total of more than 120,000 people, at 57 proton and heavy ion Therapy Center for clinical tests or treatment, and another 34 under construction.
Up to now, China has only Zibo Wan Jie tumor hospital, Shanghai with Proton heavy-ion the hospital opened 2 treatment centres, in short supply. Proton Therapy superpower United States building Proton centers reaching more than 14 have been built and under construction and up to 31.
But Proton Therapy Center in the region is difficult to meet the needs of patients, with the exception of Japan outside the large number (17, 13 opening, 4 under construction), the rest is still in its early construction phase. Korea treated cases has reached nearly 2000 people, in a leading position.
Similar to the proton therapy, Samsung Seoul hospital considering the benefits and side effects, usually uses minimal intervention surgery, if done for patients with lung cancer video-assisted Thoracoscopic surgery, for colorectal cancer patients were treated to do laparoscopic surgery, high-frequency heat treatment for liver cancer patients. Since its 2008 Cancer Center opened, over more than 6,000 patients each year to come to multidisciplinary consultation.
In Samsung Seoul hospital, cure is not the ultimate goal of health care, which extends up top to order medical examinations, down derivative outcome management.
As early as in February 2011, Korea Samsung Seoul hospital introduces top day "admission" physical examination, known as the "premium" precise examination extremely scarce in China, through the combination of precision instruments and expert levels, more traces of early detection of disease.
By signing with the two high-end hospitals in China, Samsung Seoul hospital hopes to comply with China's growing trend of overseas medical treatment.
Starting from 2011, to find a superb medical skill, quality of service, standard treatment, advanced equipment and medicines, China's overseas medical treatment market is hot, and in 2015, the inflection point: 3 times as long as a few years ago. Stanford Research Institute expects global market for overseas medical treatment reached 678.5 billion dollars in 2017.
This trend, formed the Agency in China, the hospital sent three overseas medical treatment and the platform business model, Samsung Seoul hospital is one of the representatives of the hospital.
Because it is a hospital for hospital referral, consultation, advantages of the hospital are professional and authoritative treatment are available for patients, after the management will also have unique advantages.
In fact, Korea medical advantages not only in no less than Europe and levels, particularly evident in the value for money, convenience and other features. According to the Korea International medical organization, Samsung Seoul hospital's cancer 5-year survival rate was 73.6%, much higher than the domestic 31%, even higher than the United States, but only for the United States 20%-30%.
Bio-Pharmaceutical Forum: the world's leading biopharmaceutical
On April 2, 2016, the Samsung Bioepis arthritis drug Flixabi produced by European Medicines Agency (EMA) positive opinion, means that this year sales of 8.8 billion dollars in drugs is about to enter the European market.
Samsung healthcare industry landscape is not limited to medical services, according to Samsung's plans, a leading global consumer electronics company is to be the first to transform into the world's top bio-pharmaceutical business.
Samsung's transformation logic is not complicated: choose a fast-growing industry, a scarce supply of links and many advantages of combining precision electronics manufacturing. This year, Samsung's new leader Lee Jae-in China, said: "we see information technology, drugs and biological agents after fusion with potential opportunities. "Biopharmaceutical identified as the core of Samsung's future new business.
Since 1982, United States since the FDA approval of the first recombinant biological products, in modern society with high incidence of disease, bio-industrial growth sharply.
According to statistics, the global biopharmaceutical market in 2014 from $ 180 billion will grow to us $ 290 billion in 2020, with an average annual growth rate reached 8.2%, which accounted for more than 1/4 of the overall pharmaceutical market share. At present, 7 per cent of world's 10-largest pharmaceuticals biopharmaceutical, due to effect significant, especially the treatment of incurable diseases, drugs made of this genetic factor and cell, much higher than the share of synthetic drugs and natural medicines.
But Samsung did not choose to large-scale investment in the entire path of the bio-pharmaceutical, but key investment scarcity of essential links OEM (CMO).
Chose the CMO, Samsung explained, developing biological drugs require 1 billion-$ 2 billion and take more than 10 years, even developed a new drug, production is not easy. Through professional CMO, of small research and development pharmaceutical companies can reduce equipment investment burden, lower manufacturing costs, and played a Samsung its own many years experience in precision manufacturing. In recent years, developed countries in Europe and America, and bio-venture companies use biopharmaceutical CMO production has become the trend.
Starting from 2010, Samsung biomedical 2.1 trillion won investment plan was announced. In July 2013, Samsung biopharmaceutical first factory (production of 30,000 litres) in 2015, after the pilot production. In February of that year, the single devices reached the highest levels of the second plant (production of 150,000 liters) completed in programme entered full production in the first quarter.
As CMO production facility completed at present, Samsung biopharmaceutical has been with United States BMS, and Switzerland Roche signed a contract manufacturing agreement, and consultation and cooperation with a number of bio-pharmaceutical company, founded in the 4th year is the world's 3rd CMO.
To satisfy the demand, Samsung biomedical is considering a third factory to build production reached 150,000 liters or more during the year, and plans by 2020 to ensure that the production of more than 400,000 liters, so that by 2020 the vision of becoming the world's first CMO.
In a short time you can reach the first camp, due to the biopharmaceutical CMO path transplant Samsung's accumulated experience in the electronic industry, "Samsung semiconductor cleaning lab, sophisticated construction, large plant operating experience to help biopharmaceutical investment efficiency, productivity and manufacturing cost of quick wins. "Samsung said.
Digital Health: low resources, mobile medical landscape first
Compared with medical services and CMO, this should most closely in conjunction with the consumer electronics digital medical, Samsung quietly move on until three years ago, opened the tip of the iceberg.
In May 2014, Samsung released the first digital medical platform SAMI and 24 institutions signed a medical partnership, including NIKE, CIGNA and other giants. SAMI Samsung digital medical platform, supports and watches wearable device and mobile health application for real-time data transfer, and provides API for third party developers software interface, which developers around the world, medical institutions and partners to create a digital medical care.
The application software of digital medical, Samsung developed "s Health", and Canada telemedicine network OTN cooperation, to provide users with information on diabetes management services.
In addition, Samsung mobile in vitro diagnostic instruments, digital X-ray, ultrasound, hearing aids and other medical equipment were also involved.
Considered by some critics, Samsung digital medical can be used an equation to represent that "digital medical patents + medical + platform + diabetes + wearable medical watch mobile medical Cart + smart hearing aid market = Samsung digital medical care."
It can be predicted that in the 21st century, healthcare industry is expected to become one of the core business of Samsung.
三星悄然布局医疗行业，产业格局初现 -
三星,医疗,健康 - IT资讯
全球领先电子消费品三星集团的医疗健康版图正在日益完善。
2016年5月8日，三星首尔医院与阳光融和医院达成协议，双方将在健康管理、多学科会诊、重症治疗以及人才培养等方面开展合作。
三星首尔医院由三星集团在1994年出资设立，现位列韩国五大医院之一，每年接待来自150多个国家的3万多名患者，其高端体检及重症治疗在全球名列前茅；阳光融和医院是中国首家由保险公司投资的大型综合医院，按JCI及“三甲”标准建设，是社会资本办医的典型案例。此举被视为三星集团进军中国高端医疗服务的重要步伐。
不惟医院合作，从2010-年发布23万亿韩元的能源环保及医疗健康投资计划开始，三星集团以“医疗服务+生物制药+数字医疗”三足鼎立模式转型进入前景更加广阔的医疗健康行业，历经五年低调前行，现已初步形成了具备未来发展前景的医健版图。
具体而言，在医疗服务，三星首尔医院一扫“韩国美容”的固有印象，以治愈率和性价比优势，主打“入院式”高端体检和重症治疗；在制药领域，选择最具前景的生物制药及委托生产（CMO）这一稀缺供给环节，成为世界第三大（CMO）供应商；在数字医疗，低调整合医疗、技术资源，打造了从健康管理到治疗核心的综合医疗平台。
业内分析，三大版块均瞄准医疗健康产业中最为前沿的细分市场，看似分散，实则构成了互为支撑与呼应的医健产业链。更为值得借鉴的是，三星将原有电子产业的建设、运营经验，巧妙移植到医疗健康，因此，在投资效率、生产能力和制造成本等方面具有短时间内创造世界最高竞争力的潜力，最终形成了独特的“三星转型逻辑”。
可以预见，在21世纪，医疗健康产业将成为三星的核心事业之一。
医疗服务版块：治愈率不输欧美，性价比优势明显
与阳光融和医院的合作已不是三星集团第一次向中国输出精准医疗服务的举措。
3月4日，三星首尔医院与北京明德医院达成类似协议，后者是京东方旗下的私立高端综合医院。三星集团希望借此将其重症治疗与高端体检引入中国。
事实上，一说到韩国医疗，就想到美容整形是一大误区，数据显示，在医疗卫生支出相当于美国1/4的情况下，韩国却在总预期寿命、心脏病致死等指标上取得了比美国更好的效果。欧美、中东、中国等多个国家和地区时常聘请韩国医生前往治疗。
具体至三星首尔医院，10%的韩国癌症患者、1/4肺癌患者的胸腔镜手术均在该院完成，其胃癌、结直肠癌及肝癌手术后的死亡率和复发率在韩国也是较低的。首尔医院秉承疗效显著与副作用最小化原则。
以“治癌利器”质子治疗为例，2015年，三星首尔医院引入这一先进放疗手段，它通过一台上百吨的设备，打出时速约为2/3倍光速的高能粒子，用以消灭肿瘤细胞，并极少伤及正常人体组织。
“粒子治疗合作组织”统计，截至2014年底，全球共有12万多人，在57家质子、重离子治疗中心接受临床试验或治疗，另有34家处于建设中。
截至目前，中国大陆仅有淄博万杰肿瘤医院、上海质子重离子医院2家治疗中心开业，供不应求。质子治疗第一大国美国的在建质子中心达到14家之多，已建和在建项目之和高达31家。
但亚洲地区的质子治疗中心还难以满足患者需求，除日本数量较多外（17家，13家开业，4家在建），其余地区仍处于初期建设阶段。韩国收治案例已达近2000人，处于领先地位。
与质子治疗类似，三星首尔医院综合考量疗效与副作用，通常会优先使用最少介入方法的手术，如为肺癌患者做视频胸腔镜手术、为大肠癌患者做单一腹腔镜手术、为肝癌患者做高频热治疗等。自2008年开设癌症中心以来，每年有6000多位患者前来接受多学科会诊。
而在三星首尔医院看来，治愈疾病并非医疗的终极目标，其向上延伸顶级订制体检，向下衍生愈后管理。
早在2011年2月，韩国三星首尔医院就引入了顶级多天“入院式”体检，这种名为“premium”精准体检在中国极为稀缺，力求通过精密仪器和专家水平的结合，更早期发现疾病的蛛丝马迹。
通过与中国两家高端医院的签约，三星首尔医院希望顺应中国日益高涨的海外就医趋势。
从2011年开始，为寻求精湛医术、服务质量、规范治疗、先进设备及药品，中国的海外就医市场逐渐火热，并在2015年进入拐点：3倍于数年前。斯坦福研究所预计，全球海外就医市场将在2017年达到6785亿美元。
在此热潮下，中国形成了中介派、医院派及平台派三种海外就医商业模式，三星首尔医院即是医院派代表之一。
由于是医院对医院的转诊、会诊，医院派的优势是专业，可为患者提供权威的治疗方案，在愈后管理环节亦具有独特优势。
实际上，韩国医疗的优势不仅体现在不低于欧美日水平外，性价比、便利性等特征尤为明显。据韩国国际医疗组织统计，三星首尔医院的癌症5年生存率达到73.6%，远高于国内31%，甚至高于美国，但收费仅为美国的20%-30%。
生物制药版块：转型全球顶尖生物制药商
2016年4月2日，三星Bioepis生产的关节炎药物Flixabi获得了欧洲医药局（EMA）的肯定性意见，意味着这款年销量88亿美元的药物即将进入欧洲市场。
三星医疗健康产业版图不局限于医疗服务，按照三星的规划，全球领先电子消费品公司即将率先转型为全球顶尖生物制药商。
三星的转型逻辑并不复杂：选择一个高速发展的行业、一个供给稀缺的环节，并结合自身精密电子制造的诸多优势。今年，三星新掌门李在镕在中国表示：“我们看到了将信息技术、药物和生物制剂融合一起后蕴藏的机会。” 生物制药确定为三星未来的核心新事业。
自1982年美国FDA批准第一个基因重组生物制品以来，在疾病高发的现代社会，生物产业急剧生长。
据统计，全球生物医药品市场从2014年的1800亿美元将增长至2020年的2900亿美元，年均增长率达到8.2%，届时将占整个制药市场份额的1/4以上。目前，世界10大医药品中有7个为生物医药品，由于药效显著，尤其能治疗疑难病症，这种利用遗传因子和细胞制成的药品，远高于合成药物及天然药品的占有率。
但三星没有选择大规模投资整个生物制药的路径，而是重点投资必不可少的稀缺环节委托生产（CMO）。
之所以选择CMO，三星方面解释，开发生物新药需要10亿-20亿美元，并耗费10多年时间，即使开发出新药，稳定生产也并非易事。而通过专业的CMO，既可减少中小研发药企的设备投资负担、降低制造成本，又发挥了三星自身多年精密制造的经验。近年来，在欧美发达国家，生物创投企业利用CMO生产生物药品已渐成潮流。
从2010年开始，三星即公布了生物医药2.1万亿韩元的投资计划。2013年7月，三星生物制药第一工厂（产量3万升）试生产后于2015年进入了正式生产。当年2月，单一设备达到世界最高水平的第二工厂（产量15万升）竣工，计划在今年第一季度进入正式生产。
随着CMO生产设施的陆续完工，目前，三星生物制药已经与美国BMS、瑞士Roche签署了委托生产合同，并与多个生物药企协商合作事宜，在创立第4年就成为世界第3位CMO。
为满足更多需求，三星生物制药正在考虑年内修建产量达到15万升以上的第三工厂，并计划在2020年之前确保40万升以上的产量，以便在2020年之前实现成为全球第一CMO的愿景。
之所以在短时间内即可达到世界第一阵营，缘于生物制药CMO路径移植了三星在电子产业长期积累的经验，“如三星半导体净化实验室、尖端工厂建设、超大工厂运营等经验，帮助生物制药在投资效率、生产能力和制造成本等方面迅速胜出。”三星方面表示。
数字医疗：低调整合资源，移动医疗版图初现
与医疗服务和CMO相比，在本应与电子消费结合最为紧密的数字医疗，三星却在默默前行，直至三年前才揭开冰山一角。
2014年5月，三星首度公布了数字医疗平台SAMI，并与24个机构签署了数字医疗合作伙伴关系，其中不乏NIKE、CIGNA等巨头。三星数字医疗平台SAMI，可支持腕表等可穿戴设备与手机健康应用进行实时数据传输，并面向第三方开发者提供了API软件接口，从而为全球的开发者、医疗机构以及合作伙伴营造数字医疗生态。
数字医疗的应用软件方面，三星开发出“S Health”，并与加拿大远程医疗网络OTN合作，给用户提供糖尿病管理方面的信息服务。
此外，三星在移动体外诊断仪、数字X-ray，超声波、助听器等医疗设备方面也有涉足。
有评论认为，三星数字医疗可用一个等式来表示，即“数字医疗专利+数字医疗平台+糖尿病管理+可穿戴医疗手表+移动医疗车+智能助听器市场=三星数字医疗”。
可以预见，在21世纪，医疗健康产业将有望成为三星的核心事业之一。